Biden’s office: Last known prostate cancer screening dates back to 2014

Former U.S. President Joe Biden’s prostate cancer diagnosis has come under heightened public scrutiny, especially following confirmation that his “last known” screening for the disease was in 2014.

On Tuesday, May 20, 2025. Biden’s office released a brief statement addressing growing speculation about the progression and detection of his condition.

The statement emphasized that prior to last Friday, Biden had never received a prostate cancer diagnosis.

The cancer, though treatable, has reportedly spread to his bones, indicating it has reached an advanced and incurable stage.

Biden’s aides released the updated information to quell mounting concerns and theories suggesting the disease may have been concealed during his time in the White House.

These concerns have been amplified by the late-stage nature of the diagnosis and the extended period since his last documented screening.

The official statement from Biden’s team was concise and did not include the results of his 2014 PSA (prostate-specific antigen) blood test.

It read, “President Biden’s last known PSA was in 2014. Prior to Friday, President Biden had never been diagnosed with prostate cancer.”

PSA testing is a common method used to detect early signs of prostate cancer.

Although the decision to screen, particularly in older men, remains controversial due to concerns about over diagnosis and overtreatment.

Biden’s diagnosis was announced publicly on Sunday, prompting a significant outpouring of sympathy from the public and political figures.

However, critics quickly voiced suspicions regarding whether the cancer had been known but not disclosed during his presidency.

Among them was his successor, former President Donald Trump, who, while expressing sympathy, questioned the timeline of the public disclosure.

Speaking at the White House on Tuesday, Trump remarked, “It takes a long time to get to that situation.”

He added that he was “surprised that the public wasn’t notified a long time ago.”

Despite these comments, Trump acknowledged the seriousness of Biden’s condition and said, “It’s a very sad situation and I feel very badly about it.”

The lack of clarity surrounding Biden’s medical history has also led to renewed attention to how health data is shared by presidents.

A memo from the White House physician following Trump’s most recent physical exam in April indicated that Trump’s PSA level was within normal limits.

In contrast, Biden’s White House medical reports did not include any PSA results.

This raised additional questions about the comprehensiveness of the health information released during his time in office.

PSA testing itself is not without controversy.

The U.S. Preventive Services Task Force and other medical organizations have issued guidelines recommending against routine prostate cancer screening for men aged 70 and older.

This is due to the risk of unnecessary treatment and side effects that can significantly impact quality of life.

Joe Biden, who is now 82 years old, would have fallen into this category, meaning routine PSA testing may not have been advised for him under these guidelines.

Despite the controversy surrounding its screening, prostate cancer remains a significant health issue.

It is the second-leading cause of cancer death in men, trailing only lung cancer.

According to the American Cancer Society, approximately one in eight men will be diagnosed with prostate cancer at some point in their lives.

However, if detected early, it is also one of the most treatable forms of cancer, often with high survival rates.

With the disease having already metastasized to Biden’s bones, the outlook is considerably more serious.

While advanced prostate cancer can often be managed for a number of years with treatments such as hormone therapy, chemotherapy, and newer targeted medications, it is not curable in this stage.

The statement released by Biden’s team on Tuesday appeared designed to address concerns of a possible cover-up.

It is also supposedly to clarify that there had been no previous diagnosis or indication of prostate cancer before the most recent developments.

As questions about the transparency of presidential health disclosures continue, Biden’s situation highlights the delicate balance between medical privacy and public right to know.

This is particularly when it involves the health of national leaders.

For Diaspora Digital Media Updates click on Whatsapp, or Telegram. For eyewitness accounts/ reports/ articles, write to: citizenreports@diasporadigitalmedia.com. Follow us on X (Fomerly Twitter) or Facebook